Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Immunodiagnostic Systems launches four new assays

Wed 16 September 2020 14:28 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Laboratory diagnostics specialist Immunodiagnostic Systems announced the launch of four new 'i-Tracker' assays designed to run on its automated 'IDS-iSYS' analyser on Wednesday.

The AIM-traded firm said the assays were developed by its partner Theradiag, and addressed the "rapidly growing" market of biologics drug monitoring.

It said the four i-Tracker assays, being 'i-Tracker Infliximab', 'i-Tracker Anti-Infliximab', 'i-Tracker Adalimumab' and 'i-Tracker Anti-Adalimumab', were previously launched on the 'i-Track10' analyser, which is an instrument manufactured by IDS for Theradiag.

In the six months since the Theradiag launch, the assays had undergone validation on the IDS-iSYS analyser, and were now available for use on the installed base of IDS-iSYS analysers in Europe, and other territories which accept a CE-mark accreditation.

"We are pleased to see that validation of these biologics monitoring markers has been completed successfully," said chief executive officer Jaap Stuut.

"IDS has distribution rights for these unique assays in a number of key markets, and making the kits available to our installed base of customers is a crucial step in the distribution strategy.

"These tests also complement our continued focus on auto-immune diseases, as therapeutic drug monitoring is often performed by the same immunology teams."

At 1108 BST, shares in Immunodiagnostic Systems Holdings were up 3.33% at 248p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More AIM news from ShareCast

    No results were found